Cytotoxic lymphocytes are dysregulated in multisystem inflammatory syndrome in children
Abstract
Multisystem inflammatory syndrome in children (MIS-C) presents with fever, inflammation and multiple organ involvement in individuals under 21 years following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To identify genes, pathways and cell types driving MIS-C, we sequenced the blood transcriptomes of MIS-C cases, pediatric cases of coronavirus disease 2019, and healthy controls. We define a MIS-C transcriptional signature partially shared with the transcriptional response to SARS-CoV-2 infection and with the signature of Kawasaki disease, a clinically similar condition. By projecting the MIS-C signature onto a co-expression network, we identified disease gene modules and found genes downregulated in MIS-C clustered in a module enriched for the transcriptional signatures of exhausted CD8+ T-cells and CD56dimCD57+ NK cells. Bayesian network analyses revealed nine key regulators of this module, including TBX21, a central coordinator of exhausted CD8+ T-cell differentiation. Together, these findings suggest dysregulated cytotoxic lymphocyte response to SARS-Cov-2 infection in MIS-C.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Icahn School of Medicine at Mount Sinai.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of the Icahn School of Medicine at Mount Sinai
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon request following publication in a peer-reviewed journal
Subject Area
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (201)
- Cardiovascular Medicine (2930)
- Dermatology (249)
- Emergency Medicine (439)
- Epidemiology (12734)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4577)
- Geriatric Medicine (417)
- Health Economics (729)
- Health Informatics (2914)
- Health Policy (1069)
- Hematology (388)
- HIV/AIDS (924)
- Medical Education (424)
- Medical Ethics (115)
- Nephrology (468)
- Neurology (4344)
- Nursing (236)
- Nutrition (638)
- Oncology (2266)
- Ophthalmology (645)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (500)
- Pediatrics (1196)
- Primary Care Research (495)
- Public and Global Health (6932)
- Radiology and Imaging (1526)
- Respiratory Medicine (915)
- Rheumatology (437)
- Sports Medicine (385)
- Surgery (487)
- Toxicology (60)
- Transplantation (210)
- Urology (180)